Autopsy report · NCT03484520

A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

“Strategic considerations”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 4 years 4 months before it stopped.
• 48 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

AbbVie

Sponsor type

Industry

Conditions

Cancer - Acute Myeloid Leukemia

Interventions

Venetoclax; Dinaciclib

Participants

48

Sites

13

Countries

Australia, Spain, United States

Trials that died the same way

• TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.
  “Strategic decision” (82% match in meaning)
• Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
  “Strategic Reasons” (77% match in meaning)
• Rapid Amniotic Fluid (AF) Test and a Non-Invasive Vaginal Fluid (VF) Test
  “Business Strategic Decision” (76% match in meaning)
• Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
  “Strategic business decision” (76% match in meaning)
• S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
  “Strategic development reasons” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.